Balyasny Asset Management’s CorMedix CRMD Stock Holding History

Balyasny Asset Management’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.59M	Buy	+202,370	New	+$1.6M	﹤0.01%	1945
2026 Q1	–	Sell	-75,447	Closed	-$877K	–	2978
2025 Q4	$877K	Sell	75,447 -83,583	-53%	-$924K	﹤0.01%	2256
2025 Q3	$1.85M	Buy	159,030 +101,150	+175%	+$1.22M	﹤0.01%	1840
2025 Q2	$713K	Buy	+57,880	New	+$639K	﹤0.01%	2165
2025 Q1	–	Sell	-44,270	Closed	-$359K	–	2861
2024 Q4	$359K	Buy	+44,270	New	+$442K	﹤0.01%	2316
2024 Q3	–	Sell	-16,446	Closed	-$71.2K	–	2799
2024 Q2	$71.2K	Buy	+16,446	New	+$83.5K	﹤0.01%	2423

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

OAM

Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Balyasny Asset Management's CRMD Position: Q2 2026 in Review

Balyasny Asset Management opened a new position in CorMedix (CRMD) in Q2 2026: 202,370 shares worth $1.59M. The stake represents ﹤0.01% of the portfolio and ranks #1945 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in CRMD as recently as Q4 2025.

Balyasny Asset Management first reported a position in CRMD in Q2 2024 and has held it in 6 quarters since. The position peaked at $1.85M in Q3 2025. 194 funds tracked by Wall St. Rank hold CRMD as of Q2 2026.

Balyasny Asset Management held 202,370 shares of CorMedix worth $1.59M as of Q2 2026.
CorMedix was a new Balyasny Asset Management position in Q2 2026.
CorMedix made up ﹤0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #1945 holding.
Balyasny Asset Management first reported a position in CorMedix in Q2 2024 and has held it in 6 quarters since.
Balyasny Asset Management's CorMedix position peaked at $1.85M in Q3 2025.
194 funds tracked by Wall St. Rank held CorMedix as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.